![Adrian Senderowicz](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Adrian Senderowicz
Direktor/Vorstandsmitglied bei
PUMA BIOTECHNOLOGY, INC.
Vermögen: 245 970 $ am 31.08.2026
Profil
Adrian M.
Senderowicz is currently an Independent Director at Puma Biotechnology, Inc. since 2015, a Director at Step Pharma SAS since 2021, and an Independent Director at Anavex Life Sciences Corp.
Formerly, Dr. Senderowicz was Senior Medical Director-Oncology Division at AstraZeneca PLC from 2008 to 2012, Chief Medical Officer & Senior Vice President at Cerulean Pharma, Inc. from 2015 to 2017, Chief Medical Officer & VP-Medical Development at Tokai Pharmaceuticals, Inc. from 2012 to 2013, Chief Medical Officer & Senior Vice President at Constellation Pharmaceuticals, Inc. from 2017 to 2020, Chief Medical Officer & SVP-Regulatory Affairs at Ignyta, Inc. from 2014 to 2015, Chief Medical Officer & Senior Vice President at Daré Bioscience, Inc. from 2015 to 2017, and Vice President-Global Regulatory Oncology at Sanofi from 2013 to 2014.
Other former roles include Non-Executive Director at Oncoinvent ASA (Old), Head-Prostate Cancer Clinic at National Institutes of Health, and Clinical Team Leader-Oncology Division at US Food & Drug Administration.
Education includes a doctorate from Universidad de Buenos Aires.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 12.06.2026 | 27’000 ( 0.05% ) | 245 970 $ | 31.08.2026 |
Aktive Positionen von Adrian Senderowicz
| Unternehmen | Position | Beginn |
|---|---|---|
| PUMA BIOTECHNOLOGY, INC. | Direktor/Vorstandsmitglied | 11.08.2015 |
| ANAVEX LIFE SCIENCES CORP. | Direktor/Vorstandsmitglied | - |
Step Pharma SAS
 Step Pharma SAS Pharmaceuticals: MajorHealth Technology Develops drugs for immunosuppressive therapies | Direktor/Vorstandsmitglied | 06.10.2021 |
Ehemalige bekannte Positionen von Adrian Senderowicz
| Unternehmen | Position | Ende |
|---|---|---|
| CONSTELLATION PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 22.06.2020 |
Cerulean Pharma, Inc.
 Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Design and develops nanopharmaceuticals | Technik-/Wissenschafts-/F&E-Leiter | 15.06.2017 |
| DARÉ BIOSCIENCE, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.06.2017 |
| IGNYTA INC | Technik-/Wissenschafts-/F&E-Leiter | 01.04.2015 |
| SANOFI | Corporate Officer/Principal | 01.08.2014 |
Ausbildung von Adrian Senderowicz
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
66
Beziehungen ersten Grades
14
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 14 |
|---|---|
AstraZeneca PLC
 AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Sanofi
 Sanofi Pharmaceuticals: MajorHealth Technology Engages in research, development and production of pharmaceuticals & vaccines | Health Technology |
National Institutes of Health
 National Institutes of Health General GovernmentGovernment Engages in the improvement of health and saving lives | Government |
Universidad de Buenos Aires
 Universidad de Buenos Aires Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
US Food & Drug Administration
 US Food & Drug Administration General GovernmentGovernment Operates agencies to protect health and human services | Government |
Anavex Life Sciences Corp.
 Anavex Life Sciences Corp. BiotechnologyHealth Technology Engages in the development of innovative drug compounds | Health Technology |
Tokai Pharmaceuticals, Inc.
 Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops novel proprietary therapies for the treatment of prostate cancer and other hormonally driven diseases | Health Technology |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Design and develops nanopharmaceuticals | Health Technology |
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel drugs targeting regulators of epigenetic function | Health Technology |
Puma Biotechnology, Inc.
 Puma Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a development stage company which develops biopharmaceuticals used for the treatment of cancer | Health Technology |
Ignyta, Inc.
 Ignyta, Inc. BiotechnologyHealth Technology Operates as a medicine biotechnology company which provides new drugs services for cancer patients | Health Technology |
Oncoinvent AS
 Oncoinvent AS Pharmaceuticals: MajorHealth Technology Develops alpha-emitting radiopharmaceuticals for cancer treatment | Health Technology |
Step Pharma SAS
Step Pharma SAS Pharmaceuticals: MajorHealth Technology Develops drugs for immunosuppressive therapies | Health Technology |
Daré Bioscience, Inc.
 Daré Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Provides pharmaceutical products | Health Technology |
